GIST Support International - logo

GIST Support International - XL228
GIST Imagery

XL228

manufacturer:  Exelixis
information at Exelixis website: http://www.exelixis.com/pipeline_xl228.shtml

poster at Exelixis website:
http://www.exelixis.com/eortc/posters/EORTC08_390_XL228-002.pdf

oral or intravenous: intravenous

Description from NCI drug Dictionary: A synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis. In addition, this agent may be a potent inhibitor of the T315I mutant form of the Abl protein, which is associated with the resistance of chronic myelogenous leukemia (CML) to other tyrosine kinase inhibitors. IGF1R and Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. Bcr-Abl translocation leads to constitutive activation of ABL kinase and is commonly associated with Philadelphia-positive acute lymphocytic leukemia (ALL).

Ongoing trials:  One trial which could potentially enroll a GIST patient is listed below:

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies  (NCT00526838)Phase I



back to top